CA2618747A1 - Substituted imidazole compounds as ksp inhibitors - Google Patents

Substituted imidazole compounds as ksp inhibitors Download PDF

Info

Publication number
CA2618747A1
CA2618747A1 CA002618747A CA2618747A CA2618747A1 CA 2618747 A1 CA2618747 A1 CA 2618747A1 CA 002618747 A CA002618747 A CA 002618747A CA 2618747 A CA2618747 A CA 2618747A CA 2618747 A1 CA2618747 A1 CA 2618747A1
Authority
CA
Canada
Prior art keywords
phenyl
imidazol
benzyl
amino
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002618747A
Other languages
English (en)
French (fr)
Inventor
Paul A. Barsanti
Yi Xia
Weibo Wang
Kris G. Mendenhall
Liana M. Lagniton
Savithri Ramurthy
Megan C. Phillips
Sharadha Subramanian
Rustum Boyce
Nathan M. Brammeier
Ryan Constantine
David Duhl
Annette O. Walter
Tinya J. Abrams
Paul A. Renhowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2618747A1 publication Critical patent/CA2618747A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002618747A 2005-08-09 2006-08-09 Substituted imidazole compounds as ksp inhibitors Abandoned CA2618747A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70690105P 2005-08-09 2005-08-09
US60/706,901 2005-08-09
PCT/US2006/031129 WO2007021794A1 (en) 2005-08-09 2006-08-09 Substituted imidazole compounds as ksp inhibitors

Publications (1)

Publication Number Publication Date
CA2618747A1 true CA2618747A1 (en) 2007-02-22

Family

ID=37421032

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002618747A Abandoned CA2618747A1 (en) 2005-08-09 2006-08-09 Substituted imidazole compounds as ksp inhibitors

Country Status (19)

Country Link
US (1) US7626040B2 (enExample)
EP (1) EP1912972B1 (enExample)
JP (1) JP4975745B2 (enExample)
KR (1) KR20080036611A (enExample)
CN (1) CN101253167A (enExample)
AR (1) AR056025A1 (enExample)
AT (1) ATE526324T1 (enExample)
AU (1) AU2006279991B2 (enExample)
BR (1) BRPI0614547A2 (enExample)
CA (1) CA2618747A1 (enExample)
ES (1) ES2374449T3 (enExample)
GT (1) GT200600366A (enExample)
MY (1) MY147188A (enExample)
PE (1) PE20070352A1 (enExample)
PL (1) PL1912972T3 (enExample)
PT (1) PT1912972E (enExample)
RU (1) RU2413721C9 (enExample)
TW (1) TW200800951A (enExample)
WO (1) WO2007021794A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902240B2 (en) * 2006-11-13 2011-03-08 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
EP2106399A2 (en) * 2007-01-05 2009-10-07 Novartis AG Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
CN101903365B (zh) 2007-10-19 2014-02-05 默沙东公司 用于抑制ksp驱动蛋白活性的螺缩合的1,3,4-噻二唑衍生物
US8252832B2 (en) * 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
KR20130100056A (ko) 2010-04-15 2013-09-09 노파르티스 아게 Ksp 억제제로서의 트리아졸 화합물
WO2014151030A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
JP6721507B2 (ja) * 2013-12-23 2020-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト Ksp阻害剤との抗体薬物複合体(adc)
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CN107921146A (zh) * 2015-06-23 2018-04-17 拜耳医药股份有限公司 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc)
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
CN112601553A (zh) 2018-06-18 2021-04-02 拜耳股份有限公司 具有可酶切的接头和改善的活性谱的针对cxcr5的结合剂-药物缀合物
CN109481436A (zh) * 2018-08-21 2019-03-19 广东医科大学 血栓素a2合成酶抑制剂奥扎格雷在制备治疗吸烟所致肺癌药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1998027108A2 (en) 1996-12-16 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. New amide compounds and their use as nitric oxide synthase inhibitors
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
AU746963B2 (en) * 1998-06-12 2002-05-09 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Imidazolyl derivatives
EP1686120A3 (en) * 1999-10-27 2007-05-30 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6620882B1 (en) 2000-05-02 2003-09-16 Advanced Syntech, Llc Solid support template for preparation of highly functionalized heterocycle compounds
KR20030020960A (ko) * 2000-08-01 2003-03-10 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 이미다졸일 유도체
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
RU2005100783A (ru) * 2002-06-14 2005-07-20 Мерк энд Ко., Инк. (US) Ингибиторы митотического кинезина
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
WO2004100873A2 (en) * 2003-05-07 2004-11-25 Cytokinetics, Inc. Compounds, compositions, and methods
JP2007500746A (ja) * 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
US20080132549A1 (en) 2004-04-14 2008-06-05 Pfizer Inc. Sulphur-Linked Imidazone Compounds for the Treatment of Hiv/Aids
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US7576221B2 (en) * 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives

Also Published As

Publication number Publication date
AR056025A1 (es) 2007-09-12
PL1912972T3 (pl) 2012-02-29
PE20070352A1 (es) 2007-05-30
EP1912972B1 (en) 2011-09-28
MY147188A (en) 2012-11-14
RU2413721C9 (ru) 2011-05-20
CN101253167A (zh) 2008-08-27
HK1111995A1 (en) 2008-08-22
PT1912972E (pt) 2012-01-06
RU2008108939A (ru) 2009-09-20
JP4975745B2 (ja) 2012-07-11
BRPI0614547A2 (pt) 2011-03-29
US20070037853A1 (en) 2007-02-15
ES2374449T3 (es) 2012-02-16
EP1912972A1 (en) 2008-04-23
US7626040B2 (en) 2009-12-01
KR20080036611A (ko) 2008-04-28
GT200600366A (es) 2007-05-10
TW200800951A (en) 2008-01-01
JP2009504664A (ja) 2009-02-05
ATE526324T1 (de) 2011-10-15
AU2006279991A1 (en) 2007-02-22
AU2006279991B2 (en) 2011-09-29
WO2007021794A1 (en) 2007-02-22
RU2413721C2 (ru) 2011-03-10

Similar Documents

Publication Publication Date Title
EP1765789B1 (en) N-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dimethylpropyl)benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer
AU2008205169B2 (en) Imidazole derivatives as kinesin spindle protein inhibitors (Eg-5)
EP2091926B1 (en) Substituted pyrazole and triazole compounds as ksp inhibitors
AU2005301133A1 (en) Indole and benzimidazole derivatives
AU2006279991B2 (en) Substituted imidazole compounds as KSP inhibitors
AU2011239977B2 (en) Triazole compounds as KSP inhibitors
HK1111995B (en) Substituted imidazole compounds as ksp inhibitors
MX2008001411A (en) Substituted imidazole compounds as ksp inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140716